Johnson & Johnson annual return on assets (roa)
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Return on Assets (ROA) Growth & History (JNJ)
Johnson & Johnson's return on assets (roa) was 14.13% for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-28 | 14.13% | +6.04 pp |
| 2024 | 2024-12-29 | 8.09% | −11.72 pp |
| 2023 | 2023-12-31 | 19.81% | +10.09 pp |
| 2022 | 2023-01-01 | 9.71% | −1.99 pp |
| 2021 | 2022-01-02 | 11.70% | +2.85 pp |
| 2020 | 2021-01-04 | 8.85% | −0.89 pp |
| 2019 | 2019-12-29 | 9.73% | −0.13 pp |
| 2018 | 2018-12-30 | 9.86% | +8.99 pp |
| 2017 | 2017-12-31 | 0.87% | −11.17 pp |
| 2016 | 2017-01-01 | 12.05% | +0.36 pp |
| 2015 | 2016-01-03 | 11.68% | −0.73 pp |
| 2014 | 2014-12-28 | 12.41% | +1.52 pp |
| 2013 | 2013-12-29 | 10.89% | +1.65 pp |
| 2012 | 2012-12-30 | 9.24% | +0.30 pp |
| 2011 | 2012-01-01 | 8.93% | −4.56 pp |
| 2010 | 2011-01-02 | 13.50% | −0.16 pp |
| 2009 | 2010-01-03 | 13.66% | — |
Johnson & Johnson quarterly return on assets (roa)
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-28 | 10.67% | −1.44 pp |
| Q1 2026 | 2026-03-29 | 10.66% | −1.26 pp |
| Q4 2025 | 2025-12-28 | 14.13% | +6.04 pp |
| Q3 2025 | 2025-09-28 | 13.54% | +5.01 pp |
| Q2 2025 | 2025-06-29 | 12.10% | −8.29 pp |
| Q1 2025 | 2025-03-30 | 11.93% | −8.98 pp |
| Q4 2024 | 2024-12-29 | 8.09% | −11.72 pp |
| Q3 2024 | 2024-09-29 | 8.53% | −11.77 pp |
| Q2 2024 | 2024-06-30 | 20.40% | +13.33 pp |
| Q1 2024 | 2024-03-31 | 20.91% | +14.12 pp |
| Q4 2023 | 2023-12-31 | 19.81% | +10.09 pp |
| Q3 2023 | 2023-10-01 | 20.30% | — |
| Q2 2023 | 2023-07-02 | 7.07% | — |
| Q1 2023 | 2023-04-02 | 6.80% | — |
| Q4 2022 | 2023-01-01 | 9.71% | — |
| Q3 2021 | 2021-10-03 | 10.10% | −0.32 pp |
| Q2 2021 | 2021-07-04 | 10.24% | +0.55 pp |
| Q1 2021 | 2021-04-04 | 9.13% | −2.12 pp |
| Q4 2020 | 2021-01-04 | 8.92% | −0.81 pp |
| Q3 2020 | 2020-09-27 | 10.41% | +1.32 pp |
| Q2 2020 | 2020-06-28 | 9.69% | −0.83 pp |
| Q1 2020 | 2020-03-29 | 11.25% | +1.68 pp |
| Q4 2019 | 2019-12-29 | 9.73% | −0.13 pp |
| Q3 2019 | 2019-09-29 | 9.09% | +8.10 pp |
| Q2 2019 | 2019-06-30 | 10.52% | +9.63 pp |
| Q1 2019 | 2019-03-31 | 9.57% | +8.75 pp |
| Q4 2018 | 2018-12-30 | 9.86% | +8.99 pp |
| Q3 2018 | 2018-09-30 | 0.99% | −9.70 pp |
| Q2 2018 | 2018-07-01 | 0.89% | −10.27 pp |
| Q1 2018 | 2018-04-01 | 0.83% | −10.92 pp |
| Q4 2017 | 2017-12-31 | 0.87% | −11.17 pp |
| Q3 2017 | 2017-10-01 | 10.69% | −0.96 pp |
| Q2 2017 | 2017-07-02 | 11.16% | +0.11 pp |
| Q1 2017 | 2017-04-02 | 11.74% | +0.00 pp |
| Q4 2016 | 2017-01-01 | 12.05% | +0.36 pp |
| Q3 2016 | 2016-10-02 | 11.65% | +0.56 pp |
| Q2 2016 | 2016-07-03 | 11.06% | −1.00 pp |
| Q1 2016 | 2016-04-03 | 11.74% | −0.41 pp |
| Q4 2015 | 2016-01-03 | 11.68% | −0.73 pp |
| Q3 2015 | 2015-09-27 | 11.09% | −2.28 pp |
| Q2 2015 | 2015-06-28 | 12.05% | +0.07 pp |
| Q1 2015 | 2015-03-29 | 12.15% | +0.33 pp |
| Q4 2014 | 2014-12-28 | 12.41% | +1.52 pp |
| Q3 2014 | 2014-09-28 | 13.37% | +2.90 pp |
| Q2 2014 | 2014-06-29 | 11.99% | +1.27 pp |
| Q1 2014 | 2014-03-30 | 11.82% | +3.04 pp |
| Q4 2013 | 2013-12-29 | 10.89% | +1.65 pp |
| Q3 2013 | 2013-09-29 | 10.48% | +3.11 pp |
| Q2 2013 | 2013-06-30 | 10.72% | +3.05 pp |
| Q1 2013 | 2013-03-31 | 8.78% | −0.23 pp |
| Q4 2012 | 2012-12-30 | 9.24% | +0.30 pp |
| Q3 2012 | 2012-09-30 | 7.37% | −3.48 pp |
| Q2 2012 | 2012-07-01 | 7.67% | −3.69 pp |
| Q1 2012 | 2012-04-01 | 9.01% | −3.18 pp |
| Q4 2011 | 2012-01-01 | 8.93% | −4.56 pp |
| Q3 2011 | 2011-10-02 | 10.85% | −3.48 pp |
| Q2 2011 | 2011-07-03 | 11.36% | −3.69 pp |
| Q1 2011 | 2011-04-03 | 12.19% | −2.71 pp |
| Q4 2010 | 2011-01-02 | 13.50% | — |
| Q3 2010 | 2010-10-03 | 14.33% | — |
| Q2 2010 | 2010-07-04 | 15.05% | — |
| Q1 2010 | 2010-04-04 | 14.90% | — |
Johnson & Johnson return on assets (roa) trends
Over the last five fiscal years, Johnson & Johnson's return on assets (roa) increased from 8.85% to 14.13%, a change of +5.29 percentage points. The latest reported quarter, Q2 2026, shows 10.67%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
